PT3307322T - Anticorpos anti-cp40 humanizados e as suas utilizações referência cruzada relativa às aplicações associadas - Google Patents
Anticorpos anti-cp40 humanizados e as suas utilizações referência cruzada relativa às aplicações associadasInfo
- Publication number
- PT3307322T PT3307322T PT168430668T PT16843066T PT3307322T PT 3307322 T PT3307322 T PT 3307322T PT 168430668 T PT168430668 T PT 168430668T PT 16843066 T PT16843066 T PT 16843066T PT 3307322 T PT3307322 T PT 3307322T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- humanized anti
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214411P | 2015-09-04 | 2015-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3307322T true PT3307322T (pt) | 2021-04-23 |
Family
ID=58188471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT168430668T PT3307322T (pt) | 2015-09-04 | 2016-09-02 | Anticorpos anti-cp40 humanizados e as suas utilizações referência cruzada relativa às aplicações associadas |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9974855B2 (pt) |
| EP (2) | EP3906943A1 (pt) |
| JP (3) | JP6976931B2 (pt) |
| KR (1) | KR20180044422A (pt) |
| CN (2) | CN109069621B (pt) |
| AU (2) | AU2016315873B2 (pt) |
| BR (1) | BR112018004296B1 (pt) |
| CA (1) | CA3002789A1 (pt) |
| DK (1) | DK3307322T3 (pt) |
| ES (1) | ES2887602T3 (pt) |
| HK (1) | HK1251974A1 (pt) |
| HU (1) | HUE056769T2 (pt) |
| MX (2) | MX2018002708A (pt) |
| PL (1) | PL3307322T3 (pt) |
| PT (1) | PT3307322T (pt) |
| SI (1) | SI3307322T1 (pt) |
| WO (1) | WO2017040932A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE044591T2 (hu) | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| EP3906943A1 (en) | 2015-09-04 | 2021-11-10 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
| KR20190095941A (ko) | 2016-12-19 | 2019-08-16 | 그렌마크 파머수티칼스 에스. 아. | 신규 tnfr 효능제 및 이의 용도 |
| MX2019014375A (es) | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
| AU2019217207A1 (en) | 2018-02-12 | 2020-08-27 | Diabetes-Free, Inc. | Improved antagonistic anti-human CD40 monoclonal antibodies |
| AU2018432434A1 (en) | 2018-07-20 | 2021-01-28 | Eucure (Beijing) Biopharma Co., Ltd | Anti-CD40 antibodies and uses thereof |
| CA3121291A1 (en) | 2018-11-30 | 2020-06-04 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| WO2020154627A1 (en) * | 2019-01-25 | 2020-07-30 | Promab Biotechnologies, Inc. | Epcam antibody and epcam-car-t cells |
| CN113728008B (zh) * | 2019-04-10 | 2024-04-09 | 南开大学 | 抗cd40抗体及其用途 |
| EP3966240A1 (en) * | 2019-05-08 | 2022-03-16 | Novartis AG | Anti-cd40 antibodies for use in treatment of t1dm and insulitis |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2020253722A1 (en) * | 2019-06-17 | 2020-12-24 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
| WO2021048595A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| JP2023526926A (ja) * | 2020-05-18 | 2023-06-26 | ブリストル－マイヤーズ スクイブ カンパニー | 改善された薬物動態特性を有する抗体変異体 |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| CN115812082A (zh) * | 2021-07-14 | 2023-03-17 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| CA3236827A1 (en) * | 2021-11-05 | 2023-05-11 | James KRANZ | Pharmaceutical compositions of humanized anti-cd40 antibodies |
| CA3237146A1 (en) * | 2021-11-05 | 2023-05-11 | John F. Paolini | Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof |
| WO2023133577A1 (en) * | 2022-01-10 | 2023-07-13 | Kiniksa Pharmaceuticals, Ltd. | Methods of treating or reducing risk of transplant rejection |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737433A (en) | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| DE2819094A1 (de) | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| US4384996A (en) | 1981-01-09 | 1983-05-24 | Sandoz Ltd. | Novel cyclosporins |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4576284A (en) | 1983-12-02 | 1986-03-18 | Warner-Lambert Company | Closing of filled capsules |
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| CH667274A5 (de) | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611905D0 (en) | 1986-05-15 | 1986-06-25 | Lilly Industries Ltd | Capsules |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8729153D0 (en) | 1987-12-14 | 1988-01-27 | Efamol Ltd | Fatty acid compositions |
| DE68900991D1 (de) | 1988-01-29 | 1992-04-23 | Sankyo Co | Cyclosporin-zusammensetzungen. |
| HU201567B (en) | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3919982A1 (de) | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5164495A (en) | 1991-09-18 | 1992-11-17 | Abbott Laboratories | Method for preparing a dicarboxylic acid half-acid ester of FK506 |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| ES2211884T3 (es) | 1993-10-01 | 2004-07-16 | Immunex Corporation | Anticuerpos contra el cd40. |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US20030099642A1 (en) | 1996-04-22 | 2003-05-29 | Michael J. Yellin | Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis |
| US6132978A (en) | 1995-12-19 | 2000-10-17 | National Jewish Medical And Research Center | Method to regulate CD40 signaling |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| WO1999039727A1 (en) | 1998-02-04 | 1999-08-12 | The General Hospital Corporation | Costimulatory blockade and mixed chimerism in allotransplantation |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| JP5084984B2 (ja) | 1999-02-17 | 2012-11-28 | シーエスエル、リミテッド | 免疫原複合体およびそれに関する方法 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU3662101A (en) | 2000-02-01 | 2001-08-14 | Tanox Inc | Cd40-binding apc-activating molecules |
| US20020031512A1 (en) | 2000-04-19 | 2002-03-14 | M. C. Pasch | CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| ES2586206T3 (es) | 2000-06-19 | 2016-10-13 | Beth Israel Deaconess Medical Center | Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T |
| EP1717251B1 (en) | 2000-10-02 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Therapy for B-cell malignancies using human anti-CD40 antibodies |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| DE602004028272D1 (de) | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| ATE516819T1 (de) | 2003-11-04 | 2011-08-15 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von b-zell-bedingtem krebs |
| US20070110754A1 (en) | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| DK1707627T3 (da) | 2003-12-25 | 2012-12-17 | Kyowa Hakko Kirin Co Ltd | Antagonistisk anti-CD40-antistofmutant. |
| RS51908B (en) | 2004-02-06 | 2012-02-29 | University Of Massachusetts | CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| BRPI0606790C8 (pt) | 2005-02-02 | 2021-05-25 | Ct Disease Contr & Prevention | anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição |
| AU2006249305B2 (en) | 2005-05-26 | 2012-10-18 | Genentech, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| JP2008546647A (ja) | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−ｃｄ１９抗体治療 |
| CN101325970B (zh) | 2005-11-01 | 2013-08-14 | 诺华有限公司 | 抗cd40抗体的应用 |
| CN101351478A (zh) | 2005-11-01 | 2009-01-21 | 诺华有限公司 | 抗cd40抗体的应用 |
| CA2632698A1 (en) * | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using cd40 binding agents |
| SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| EP2073785B1 (en) | 2006-09-29 | 2018-05-30 | Union Carbide Chemicals & Plastics Technology Corporation | Quaternized cellulose ethers for personal care products |
| WO2008118356A2 (en) | 2007-03-22 | 2008-10-02 | Biogen Idec Ma Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| RU2491095C2 (ru) | 2007-11-09 | 2013-08-27 | Новартис Аг | Применения анти-cd40-антител |
| EP2245065A1 (en) | 2008-01-23 | 2010-11-03 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| DK2367849T3 (en) | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | METHOD OF TREATING NEURODEGENERATIVE DISEASES |
| WO2010104761A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| US8591900B2 (en) * | 2010-03-31 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Anti-CD40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| ES2734076T3 (es) | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| HUE044591T2 (hu) * | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
| LT2699601T (lt) | 2011-04-21 | 2018-03-26 | Bristol-Myers Squibb Company | Antikūnų polipeptidai, kurie antagonizuoja cd40 |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| WO2016199146A1 (en) | 2015-06-09 | 2016-12-15 | B. G. Negev Technologies And Applications Ltd | A controlled release system for pulmonary delivery of surfactant protein d |
| EA035268B1 (ru) | 2015-06-29 | 2020-05-22 | Бристол-Маерс Сквибб Компани | Антитела к cd40 |
| EP3906943A1 (en) * | 2015-09-04 | 2021-11-10 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
-
2016
- 2016-09-02 EP EP21156562.7A patent/EP3906943A1/en active Pending
- 2016-09-02 BR BR112018004296A patent/BR112018004296B1/pt active IP Right Grant
- 2016-09-02 JP JP2018512313A patent/JP6976931B2/ja active Active
- 2016-09-02 SI SI201631164T patent/SI3307322T1/sl unknown
- 2016-09-02 HU HUE16843066A patent/HUE056769T2/hu unknown
- 2016-09-02 DK DK16843066.8T patent/DK3307322T3/da active
- 2016-09-02 CN CN201680064574.2A patent/CN109069621B/zh active Active
- 2016-09-02 CA CA3002789A patent/CA3002789A1/en active Pending
- 2016-09-02 WO PCT/US2016/050114 patent/WO2017040932A1/en active Application Filing
- 2016-09-02 EP EP16843066.8A patent/EP3307322B1/en active Active
- 2016-09-02 MX MX2018002708A patent/MX2018002708A/es unknown
- 2016-09-02 KR KR1020187009524A patent/KR20180044422A/ko not_active Application Discontinuation
- 2016-09-02 AU AU2016315873A patent/AU2016315873B2/en active Active
- 2016-09-02 CN CN202211072946.XA patent/CN116063481A/zh active Pending
- 2016-09-02 PT PT168430668T patent/PT3307322T/pt unknown
- 2016-09-02 ES ES16843066T patent/ES2887602T3/es active Active
- 2016-09-02 PL PL16843066T patent/PL3307322T3/pl unknown
-
2017
- 2017-12-01 US US15/829,352 patent/US9974855B2/en active Active
-
2018
- 2018-03-02 MX MX2022015631A patent/MX2022015631A/es unknown
- 2018-04-17 US US15/955,393 patent/US10201608B2/en active Active
- 2018-09-04 HK HK18111292.2A patent/HK1251974A1/zh unknown
- 2018-12-27 US US16/234,110 patent/US10772958B2/en active Active
-
2020
- 2020-08-14 US US16/994,249 patent/US11439706B2/en active Active
-
2021
- 2021-07-20 JP JP2021119613A patent/JP2021168685A/ja active Pending
-
2022
- 2022-08-08 US US17/818,188 patent/US20220387587A1/en active Pending
- 2022-10-04 AU AU2022241635A patent/AU2022241635A1/en active Pending
-
2023
- 2023-05-22 JP JP2023084151A patent/JP2023103460A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251974A1 (zh) | 人源化抗cd40抗體及其用途 | |
| HK1248718A1 (zh) | 抗cd40抗體及其用途 | |
| IL262092A (en) | Human anti-pacap antibodies and their use | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL251537A0 (en) | Human anti-ox40 antibodies and their uses | |
| IL263223A (en) | Antibodies against cd40 and their uses | |
| HK1258375A1 (zh) | 人源化抗-cll-1抗體 | |
| IL284291A (en) | Anti-acth antibodies from humans and their use | |
| IL256579A (en) | Human antibodies | |
| PT3101131T (pt) | Anticorpo antitranstirretina humanizado | |
| IL262776A (en) | Human anti-il-1r3 antibodies | |
| IL258924A (en) | Humanized anti-Dicoff-related protein 2 antibody and uses thereof | |
| EP3197915A4 (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
| EP3481863A4 (en) | HUMANIZED ANTI-S100A9 ANTIBODIES AND USES THEREOF | |
| GB201511196D0 (en) | Monoclonal antibodies |